EA201992869A1 - WAYS OF TREATMENT OF PATIENTS WITH FABRY DISEASE, WHICH HAVE A KIDNEY FAILURE - Google Patents
WAYS OF TREATMENT OF PATIENTS WITH FABRY DISEASE, WHICH HAVE A KIDNEY FAILUREInfo
- Publication number
- EA201992869A1 EA201992869A1 EA201992869A EA201992869A EA201992869A1 EA 201992869 A1 EA201992869 A1 EA 201992869A1 EA 201992869 A EA201992869 A EA 201992869A EA 201992869 A EA201992869 A EA 201992869A EA 201992869 A1 EA201992869 A1 EA 201992869A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fabry disease
- patients
- ways
- treatment
- patient
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 title abstract 2
- 201000006370 kidney failure Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 101710168454 Beta-galactosidase A Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 1
- 229950007469 migalastat Drugs 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Предусмотрены способы лечения болезни Фабри у пациента, у которого имеется почечная недостаточность и/или повышенная протеинурия. Некоторые способы предусматривают введение пациенту от приблизительно 100 до приблизительно 150 мг эквивалента свободного основания мигаластата или его соли с частотой один раз в два дня. Некоторые способы также обеспечивают стабилизацию функции почек, уменьшение индекса массы левого желудочка, уменьшение уровня глоботриаозилсфингозина в плазме крови и/или увеличение активности -галактозидазы A у пациента.Methods of treating Fabry disease in a patient who has renal failure and / or increased proteinuria are provided. Some methods include administering to the patient from about 100 to about 150 mg of the equivalent of free base of migalastat or its salt with a frequency of once every two days. Some methods also provide stabilization of renal function, a decrease in the left ventricular mass index, a decrease in plasma globothiaosylsphingosine and / or an increase in β-galactosidase A activity in a patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/992,336 US10251873B2 (en) | 2017-05-30 | 2018-05-30 | Methods of treating fabry patients having renal impairment |
| PCT/US2018/035032 WO2018222655A1 (en) | 2017-05-30 | 2018-05-30 | Methods of treating fabry patients having renal impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992869A1 true EA201992869A1 (en) | 2020-03-27 |
Family
ID=69942834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992869A EA201992869A1 (en) | 2018-05-30 | 2018-05-30 | WAYS OF TREATMENT OF PATIENTS WITH FABRY DISEASE, WHICH HAVE A KIDNEY FAILURE |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA201992869A1 (en) |
-
2018
- 2018-05-30 EA EA201992869A patent/EA201992869A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003496A1 (en) | Treatment methods for patients with Fabry disease who have kidney failure. | |
| MX2023005455A (en) | Methods of treating heart failure by administering omecamtiv mecarbil. | |
| MX2023012450A (en) | Esketamine for the treatment of depression. | |
| EA202090955A1 (en) | METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS | |
| MX395523B (en) | TREATMENT OF FABRY DISEASE IN UNTREATED AND PREVIOUSLY TREATED PATIENTS WITH ERT. | |
| EA201892075A1 (en) | COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS | |
| AR120055A1 (en) | METHODS TO TREAT FABRY'S DISEASE IN PATIENTS WITH KIDNEY FAILURE | |
| EA202090564A1 (en) | METHODS FOR STRENGTHENING AND / OR STABILIZING THE CARDIAC FUNCTION IN PATIENTS WITH FABRIC DISEASE | |
| AR114392A1 (en) | TREATMENT OF PATIENTS WITH CLASSIC FABRY DISEASE | |
| MX2018001435A (en) | TREATMENT METHODS OF LENNOX-GASTAUT SYNDROME WITH FENFLURAMINE. | |
| MX2020006284A (en) | Bis-choline tetrathiomolybdate for treating wilson disease. | |
| EA202090242A1 (en) | TREATMENT OF FABRY DISEASE IN FZT-NAIVE AND FZT-TREATED PATIENTS | |
| CL2022000786A1 (en) | Treatment methods to modify hemodynamics | |
| WO2021007314A3 (en) | Treatment of cancer | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| EA202092540A1 (en) | COMBINATIONS FOR CANCER TREATMENT | |
| EA202193276A1 (en) | METHODS FOR THE TREATMENT OF CHOLANGIOCARCINOMA | |
| EP4327869A3 (en) | Methods of treating fabry patients having renal impairment | |
| EA201992869A1 (en) | WAYS OF TREATMENT OF PATIENTS WITH FABRY DISEASE, WHICH HAVE A KIDNEY FAILURE | |
| CL2021000444A1 (en) | Methods to reduce the risk of diabetes in patients treated for diseases related to high cholesterol. | |
| EA202190751A1 (en) | METHODS FOR TREATMENT OF MYELOPROLIFERATIVE DISORDERS | |
| DE60111622D1 (en) | ISOLATED DOSE THERAPIES WITH VULNERABLE ACTIVITY | |
| EA201990559A1 (en) | COMBINED THERAPY | |
| EA202090416A1 (en) | METHODS FOR TREATING GASTROPARESIS SYMPTOMS USING A VELUSETRAGA | |
| EA202090452A1 (en) | COMPOUNDS FOR TREATMENT OF DISEASE VON HIPPEL-LINDAU |